TrialEuropean journal of clinical pharmacology2012

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Teddy Kosoglou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.